by Raynovich Rod | Jun 4, 2013 | BIOgraph, Biopharmaceuticals
Apparently ASCO Is “Sell On the News” Trigger Another lackluster trading day with profit taking; the IBB is down 2.3% and trading near its May bottom with a pronounced topping pattern.Moreover many funds and indices now own biotech stocks so without the...
by Rod Raynovich | Jul 21, 2010 | 2020-21 Life Science Portfolios, BIOgraph
Gilead (GILD) has finally caught some bids today up 0.5% on a volume of 23M (Ave. volume 12M) shares! Among the supporters of the stock are Leerink Swann who maintain their “Market Outperform” and price target of low 40’s and JPMorgan who reiterate...
by Rod Raynovich | Apr 21, 2010 | BIOgraph
Healthcare Reform Impact on Gilead HIV Product Sales Surprises Analysts Gilead Sciences (GILD) lowered its 2010 sales forecast to a range of $7.4-$7.5B from $7.6-$7.8B citing recently enacted healthcare legislation. Net income for the quarter ended March 31 jumped...